February 2023
Clinical Research Training Scholarships (CRTS) Awarded
Paula Barreras, MD, neuroimmunology fellow at Johns Hopkins Hospital and Erika Williams, MD, PhD, neuromuscular fellow at Massachusetts General Brigham are receiving the inaugural Clinical Research Training Scholarships (CRTS) in peripheral neuropathy. Through these awards, FPN is providing $300,000 in PN research funding.
COVID & PN: A Case Study
A recent study on small fiber neuropathy associated with SARS-CoV-2 infection was published, noting that most patients who contracted PN from COVID-19 saw their painful symptoms improve significantly with treatment. The study also shows that there may not be as strong a causative link between COVID-19 infection and Guillain-Barré syndrome, as with certain other viruses.
What is Zone 2 Exercise and Its Benefits?
In the past decade, scientists, physiologists, and coaches have re-embraced the fitness benefits of slow, steady, “Zone 2” cardio—exercise that keeps your heart rate in a zone between 60 and 70 percent of your overall maximum heart rate.
As with any new exercise program, please check in with your doctor to make sure that these activities are right for you. For more tips, please visit the FPN webpage dedicated to exercise for patients with PN.
PN Book Fundraiser: Order by Feb. 21
Best-selling author and FPN friend, Will Schwalbe, has written a new book, “We Should Not Be Friends.” Chronicling a 40-year friendship, the last quarter of the book also explores the author’s experiences getting diagnosed with, and living with, small fiber neuropathy.
More information about the book, and the link to pre-order, can be found here.
A donation of $10 for every book ordered prior to its publication date on February 21 will be made to FPN by an anonymous donor who admires FPN’s work. Please notify us at [email protected] if you purchase a book so we can track numbers for the donor match.
FPN Webinar: Idiopathic PN
Featuring Norman Latov, MD, PhD, this webinar will cover idiopathic neuropathy, its definition and diagnosis. During this program, Dr. Latov will explain how to tell if it’s progressive and what do if it keeps getting worse. Dr. Latov will also talk about when to consider undergoing a nerve and muscle biopsy and what might those tests show, as well as reviewing some off label or experimental therapies and also evaluating alternative therapies.
Wednesday, February 22, 1 – 2 p.m. Eastern Time
PNS Training Grant for Young Investigators
The Peripheral Nerve Society (PNS) recently launched a grant initiative to support junior clinical investigators and their research. To learn more about eligibility, criteria, and application deadlines, please go to the PNS Training Grants webpage.
Now Recruiting: CIPN Study
AlgoTherapeutix is a pharmaceutical company currently developing a compound (ATX01) consisting in a topical formulation of an active product (amitriptyline) aimed to relieve pain in patients suffering from neuropathic pain. This study will assess the efficacy and tolerability of ATX01 in adult patients with chemotherapy-induced peripheral neuropathy.
To learn if you qualify, please email [email protected].